Logo

Log In Sign Up |  An official publication of: American College of Emergency Physicians
Navigation
  • Home
  • Multimedia
    • Podcasts
    • Videos
  • Clinical
    • Airway Managment
    • Case Reports
    • Critical Care
    • Guidelines
    • Imaging & Ultrasound
    • Pain & Palliative Care
    • Pediatrics
    • Resuscitation
    • Trauma & Injury
  • Resource Centers
    • mTBI Resource Center
  • Career
    • Practice Management
      • Benchmarking
      • Reimbursement & Coding
      • Care Team
      • Legal
      • Operations
      • Quality & Safety
    • Awards
    • Certification
    • Compensation
    • Early Career
    • Education
    • Leadership
    • Profiles
    • Retirement
    • Work-Life Balance
  • Columns
    • ACEP4U
    • Airway
    • Benchmarking
    • Brief19
    • By the Numbers
    • Coding Wizard
    • EM Cases
    • End of the Rainbow
    • Equity Equation
    • FACEPs in the Crowd
    • Forensic Facts
    • From the College
    • Images in EM
    • Kids Korner
    • Medicolegal Mind
    • Opinion
      • Break Room
      • New Spin
      • Pro-Con
    • Pearls From EM Literature
    • Policy Rx
    • Practice Changers
    • Problem Solvers
    • Residency Spotlight
    • Resident Voice
    • Skeptics’ Guide to Emergency Medicine
    • Sound Advice
    • Special OPs
    • Toxicology Q&A
    • WorldTravelERs
  • Resources
    • ACEP.org
    • ACEP Knowledge Quiz
    • Issue Archives
    • CME Now
    • Annual Scientific Assembly
      • ACEP14
      • ACEP15
      • ACEP16
      • ACEP17
      • ACEP18
      • ACEP19
    • Annals of Emergency Medicine
    • JACEP Open
    • Emergency Medicine Foundation
  • About
    • Our Mission
    • Medical Editor in Chief
    • Editorial Advisory Board
    • Awards
    • Authors
    • Article Submission
    • Contact Us
    • Advertise
    • Subscribe
    • Privacy Policy
    • Copyright Information

Tainted Synthetic Cannabis Leads to Coagulopathy Outbreak

By Arkady Rasin, MD; Jason Devgun, MD; and Theresa Kim, MD | on October 16, 2018 | 0 Comment
CME CME Now Features
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
Print-Friendly Version
Tainted Synthetic Cannabis Leads to Acquired Coagulopathy Outbreak
ILLUSTRATION: Chris Whissen & SHUTTERSTOCK.com

CME Now

You Might Also Like
  • Intoxication from Synthetic-Cannabinoid-Receptor Agonists Often Missed
  • Case Report: Fear of COVID-19 Leads to Gangrene
  • Opinion: Emergency Physicians Need Better Education on Medical Cannabis
Explore This Issue
ACEP Now: Vol 37 – No 10 – October 2018

The Case

After entering the room, it is clear something unusual is going on. This previously healthy 27-year-old has large blood-filled blisters in her mouth. In front of her, she carries a basin into which she is continuously spitting up blood, saliva, and clots.

She had presented to another emergency department two days earlier with complaints of hematuria and flank pain. After a negative CT scan of her abdomen and pelvis, she was given a provisional diagnosis of urinary tract infection and hematuria and discharged home with a prescription for nitrofurantoin. Apart from the recently prescribed antibiotic, she denies any other medications or supplements.

Her physical exam reveals a pale, ill-appearing, and uncomfortable female. Large hemorrhagic bullae fill her mouth, particularly around the gingiva and sides of the tongue. Cutaneous findings include scattered ecchymoses and an oozing abrasion on her right upper extremity. The rest of the physical exam is unremarkable.

Initial labs are normal other than a hemoglobin and hematocrit that are slightly elevated. Similarly, liver function tests are unremarkable. The coagulation study results are taking much longer than expected. A urine toxicology screen is negative for opioids, benzodiazepines, phencyclidine, and cannabis.

Additional social history reveals she smokes marijuana daily, but because she is trying to find employment, she recently switched to smoking synthetic cannabinoids (ie, “spice”) to avoid detection on pre-employment urine drug screens. She denies any other recreational drug use.

She reports that spice is sold under a variety of names in small sealed packets she buys from several corner markets throughout the city. The packaging varies, and she reports smoking multiple brands. Sometimes they are labeled as other substances such as Kratom, but the patient states it is a well-known fact these packages actually contain synthetic marijuana. The spice is clearly different from the regular marijuana she used to smoke. She noted a brief, more intense high and found herself smoking synthetic cannabinoids multiple times daily.

Finally, her coagulation results come in: Her activated partial thromboplastin time is 92 seconds, her prothrombin time (PT) is >120 seconds, and her international normalized ratio (INR) is >20. She is given four units of fresh frozen plasma (FFP) and 10 mg of IV vitamin K1.

Despite a negative past medical history or anticoagulant use, coumarin anticoagulant poisoning is suspected. Oral vitamin K1 (50 mg three times daily) is started, consistent with management from previous reports of intentional warfarin overdoses.1

Pages: 1 2 3 4 | Single Page

Topics: brodifacoumCannabisCase PresentationCase ReportscoagulopathycoumarinMarijuanarat poisonrodenticidewarfarin

Related

  • Two Cases of Female Patients with Peritonitis

    April 23, 2025 - 0 Comment
  • Case Report: Murine Typhus Presents as Severe Pneumonia and Sepsis

    February 19, 2025 - 0 Comment
  • Case Report: Acute Kratom Withdrawal

    February 11, 2025 - 0 Comment

Current Issue

ACEP Now May 03

Read More

No Responses to “Tainted Synthetic Cannabis Leads to Coagulopathy Outbreak”

Leave a Reply Cancel Reply

Your email address will not be published. Required fields are marked *


*
*

Wiley
  • Home
  • About Us
  • Contact Us
  • Privacy
  • Terms of Use
  • Advertise
  • Cookie Preferences
Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 2333-2603